Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Regeneron Pharmaceuticals    REGN

REGENERON PHARMACEUTICALS

(REGN)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Regeneron Pharmaceuticals : , Sanofi Get Positive CHMP Opinion for Dupixent

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/20/2019 | 07:08am EDT

By Chris Wack

Regeneron Pharmaceuticals and Sanofi said Friday the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion for Dupixent dupilumab in a third indication.

The companies said CHMP recommended Dupixent be approved as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe chronic rhinosinusitis with nasal polyposis for whom therapy with systemic corticosteroids and/or surgery don't provide adequate disease control.

If approved, Dupixent would be the first biologic medicine available in the European Union to treat these patients.

Regeneron and Sanofi said the positive CHMP opinion is based on two pivotal Phase 3 trials that evaluated Dupixent 300 mg every two weeks plus standard-of-care intranasal corticosteroids compared to placebo plus intranasal corticosteroids. A final decision on the Dupixent application by the European Commission is expected in the coming months.

Write to Chris Wack at chris.wack@wsj.com

Stocks mentioned in the article
ChangeLast1st jan.
REGENERON PHARMACEUTICALS -0.46% 300.19 Delayed Quote.-19.26%
SANOFI -1.10% 82.8 Real-time Quote.10.65%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on REGENERON PHARMACEUTICALS
08:31aREGENERON PHARMACEUTICALS : Announces Upcoming Investor Conference Presentations
PR
10/10REGENERON PHARMACEUTICALS : to Report Third Quarter 2019 Financial and Operating..
PR
09/23REGENERON PHARMACEUTICALS : CHMP Recommends Approval of Dupixent for Severe Chro..
AQ
09/23REGENERON PHARMACEUTICALS : Lancet Publishes Results from Two Positive Phase 3 T..
AQ
09/23SANOFI : - CHMP recommends approval of Dupixent for severe chronic rhinosinusiti..
AQ
09/20REGENERON PHARMACEUTICALS : The Lancet Publishes Results from Two Positive Phase..
PU
09/20REGENERON PHARMACEUTICALS : Sanofi Get Positive CHMP Opinion for Dupixent
DJ
09/20REGENERON PHARMACEUTICALS : CHMP Recommends Approval of Dupixent® (dupilumab) fo..
PR
09/19Animal health sector aims to emulate Zoetis biotech leap
RE
09/18REGENERON PHARMACEUTICALS : Educational Campaign Helps Teens and Their Caregiver..
PR
More news
Financials (USD)
Sales 2019 7 657 M
EBIT 2019 2 261 M
Net income 2019 1 952 M
Finance 2019 5 857 M
Yield 2019 -
P/E ratio 2019 17,5x
P/E ratio 2020 14,4x
EV / Sales2019 3,54x
EV / Sales2020 3,11x
Capitalization 32 998 M
Chart REGENERON PHARMACEUTICALS
Duration : Period :
Regeneron Pharmaceuticals Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends REGENERON PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 375,45  $
Last Close Price 300,19  $
Spread / Highest target 65,2%
Spread / Average Target 25,1%
Spread / Lowest Target 2,93%
EPS Revisions
Managers
NameTitle
Leonard S. Schleifer Co-President, Chief Executive Officer & Director
George Damis Yancopoulos Co-President, Director & Chief Scientific Officer
P. Roy Vagelos Chairman
Robert E. Landry Chief Financial Officer & Executive VP-Finance
Michael S. Brown Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
REGENERON PHARMACEUTICALS-19.26%32 998
GILEAD SCIENCES4.28%82 611
VERTEX PHARMACEUTICALS6.26%45 680
WUXI APPTEC CO., LTD.68.13%20 570
GENMAB32.08%13 649
NEUROCRINE BIOSCIENCES, INC.35.63%8 869